Colchicine – from Gout to Covid-19
Journal for Quality in Public Health · 31.05.2022 · 5 (2) · 779-785
DOI: 10.30994/jqph.v5i2.385 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for Quality in Public Health, online erschienen am 31.05.2022. Verfasst von Ekadana Prayoga Suryadi und 4 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Abstract (Originalsprache)
Colchicine is a toxic and carcinogenic alkaloid obtained from the plant extract Colchium autumnale and has been used to treat arthritis (gout) for centuries. The results of clinical trials show that low-dose colchicine is effective for the management of acute gout as well as for long-term maintenance profiling (53) and the use of colchicine is known to reduce the symptoms of inflammatory responses related to COVID-19 and reduce the frequency of other manifestations such as pulmonary infiltrates, headaches and arthralgia. However, so far studies have shown that colchicine is not used as an initial or primary treatment to treat COVID-19 but as a treatment that is "off-label" in response to hyper-inflammation caused by the release of cytokines (52).
Zitieren
APA
Suryadi, E. P., Thiotansen, K. J., Saputra, R. H., Angeline, P., & Yolanda, N. (2022). Colchicine – from Gout to Covid-19. Journal for Quality in Public Health, 5(2), 779-785. https://doi.org/10.30994/jqph.v5i2.385
Vancouver
Suryadi EP, Thiotansen KJ, Saputra RH, Angeline P, Yolanda N. Colchicine – from Gout to Covid-19. Journal for Quality in Public Health. 2022;5(2):779-785. doi:10.30994/jqph.v5i2.385
BibTeX
@article{Suryadi2022,
author = {Suryadi, Ekadana Prayoga and Thiotansen, Keith Justine and Saputra, Reynaldi Hardianto and Angeline, Priscilla and Yolanda, Novia},
title = {Colchicine – from Gout to Covid-19},
journal = {Journal for Quality in Public Health},
year = {2022},
volume = {5},
number = {2},
pages = {779--785},
doi = {10.30994/jqph.v5i2.385}
}
EUVIMED